Adoption of immune checkpoint inhibitors (ICI) for unresectable locally advanced or metastatic urothelial carcinoma (u/mUC): A retrospective assessment of community oncology practices.
2021
293Background: ICI approval provided new treatment options for patients (pts) with u/mUC. We aimed to assess the adoption of ICI and describe 1L treatment patterns in the US community oncology sett...
Keywords:
-
Correction
-
Source
-
Cite
-
Save
0
References
0
Citations
NaN
KQI